Table 3.

Subset analyses of progression-free survival (PFS) benefit by age in several pivotal phase III studies including patients with mRCC.

	Experimental arm	Control arm	Age Group	HR*
TARGET(24)	Sorafenib	Placebo	< 70	0.55
			≥ 70	0.43
VEGF105192(9)	Pazopanib	Placebo	< 65	0.41
			≥ 65	0.52
RECORD-1(8)	Everolimus	Placebo	< 65	0.33
			≥ 65	0.19

^*The hazard ration (HR) expressed refers to the relative PFS benefit of the experimental arm relative to the control arm.